


International Digestive Endoscopy Network 2020

Name	Jaihwan Kim	
Country	Korea	
Organization	Seoul National University	
Current Position	Associate professor	

Educational Background

Medical Graduate (M.D.), College of Medicine, Seoul National University, Korea, 2002
 Master of Medicine, Dept. of Internal Medicine, College of Medicine, Seoul National University, Korea, 2012
 Doctor of Medicine, Dept. of Internal Medicine, College of Medicine, Seoul National University, Korea, 2020

Professional Experiences

Internship, Seoul National University Hospital	Mar, 2002 ~ Feb, 2003
Medical Officer, Republic of Korea Army	Mar, 2003 ~ Apr. 2006
Residency, Dept. of Internal Medicine, Seoul National University Hospital	May, 2006 ~ Feb, 2010
Fellowship, Gastroenterology, Dept. of Internal Medicine, Seoul National University Hospital	Mar, 2010~Feb, 2012
Assistant professor, Gastroenterology, Dept. of Internal Medicine, Kangwon National University Hospital	Mar, 2012~June, 2013
Assistant professor, Gastroenterology, Dept. of Internal Medicine, Seoul National University Bundang Hospital	July, 2013~August, 2017
Associate professor, Gastroenterology, Dept. of Internal Medicine, Seoul National University Bundang Hospital	September, 2017 ~
Visiting Scholar, Dept. of Data Science, Dana Farber Cancer Institute	Nov, 2017 ~ Feb, 2019

Professional Organizations

The Korean Society of Gastroenterology, Member of Scientific Committee
 The Korean Society of Gastrointestinal Endoscopy, Member of Membership Committee and Quality Management Committee
 The Korean Pancreatobiliary Association, Member of Scientific Committee, Publication Committee, New Medical Technology Research Committee, and Educational Committee

Main Scientific Publications

1. Jang ES, Lee DH, Kim J, et al. Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. *Hepatogastroenterology* 2009;56:1304-9.
2. Kim J, Choi IJ, Kim CG, et al. Self-expandable metallic stent placement for malignant obstruction in patients with locally recurrent gastric cancer. *Surg Endosc* 2011;25:1505-13.
3. Kim J, Lee WJ, Lee SH, et al. Clinical features of 20 patients with curatively resected biliary neuroendocrine tumours. *Dig Liver Dis* 2011;43:965-70.
4. Kim J, Lee SH, Paik WH, et al. Clinical outcomes of patients who experienced perforation associated with endoscopic retrograde cholangiopancreatography. *Surg Endosc* 2012;26:3293-300.
5. Kim J, Ryu JK, Ahn DW, et al. Results of repeat endoscopic retrograde cholangiopancreatography after initial biliary cannulation failure following needle-knife sphincterotomy. *J Gastroenterol Hepatol* 2012;27:516-20.
6. Ahn DW, Lee SH, Kim J, et al. Long-term outcome of cystic lesions in the pancreas: a retrospective cohort study. *Gut Liver* 2012;6:493-500.
7. Paik WH, Lee SH, Ryu JK, et al. Long-term clinical outcome of biliary cast syndrome in liver transplantation recipients. *Liver Transpl* 2012.
8. Ahn DW, Ryu JK, Kim J, et al. Endoscopic papillectomy for benign ampullary neoplasms: how can treatment outcome be predicted? *Gut Liver* 2013;7:239-45.
9. Ahn DW, Ryu JK, Kim J, et al. Inflexinol reduces severity of acute pancreatitis by inhibiting nuclear factor-kappaB activation in cerulein-induced pancreatitis. *Pancreas* 2013;42:279-84.
10. Paik WH, Ryu JK, Song BJ, et al. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm. *J Korean Med Sci* 2013;28:750-4.

11. Son JH, Kim J, Lee SH, et al. The optimal duration of preoperative biliary drainage for periampullary tumors that cause severe obstructive jaundice. *Am J Surg* 2013;206:40-6.
12. Park JK, Paik WH, Ryu JK, et al. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. *PLoS One* 2013;8:e78977.
13. Kim J, Ryu JK, Park JM, et al. Clinical factors associated with accuracy of EUS-FNA for pancreatic or peripancreatic solid mass without on-site cytopathologists. *J Gastroenterol Hepatol* 2014;29:887-92.
14. Kim J, Ryu JK, Kim C, et al. Is there any role of positron emission tomography computed tomography for predicting resectability of gallbladder cancer? *J Korean Med Sci* 2014;29:680-4.
15. Paik WH, Ryu JK, Park JM, et al. Which is the better treatment for the removal of large biliary stones? Endoscopic papillary large balloon dilation versus endoscopic sphincterotomy. *Gut Liver* 2014;8:438-44.
16. Lee YS, Paik KH, Kim HW, et al. Comparison of Endoscopic Ultrasonography, Computed Tomography, and Magnetic Resonance Imaging for Pancreas Cystic Lesions. *Medicine (Baltimore)* 2015;94:e1666.
17. Lee YS, Kang BK, Hwang IK, et al. Long-term Outcomes of Symptomatic Gallbladder Sludge. *J Clin Gastroenterol* 2015;49:594-8.
18. Hwang IK, Lee YS, Kim J, et al. Do we really need additional contrast-enhanced abdominal computed tomography for differential diagnosis in triage of middle-aged subjects with suspected biliary pain. *Medicine (Baltimore)* 2015;94:e546.
19. Kim J, Lee YS, Hwang IK, et al. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma. *J Korean Med Sci* 2015;30:259-63.
20. Yoon H, Lee DH, Jang ES, et al. Optimal initiation of Helicobacter pylori eradication in patients with peptic ulcer bleeding. *J Korean Med Sci* 2015;21:2497-503.
21. Hwang IK, Kang BK, Lee YS, et al. Postoperative early thromboembolism as a prognostic indicator in patients with curatively resected pancreatic cancer. *Am J Surg* 2015;210:871-7.
22. Kim HW, Lee JC, Paik KH, et al. Initial Metastatic Site as a Prognostic Factor in Patients With Stage IV Pancreatic Ductal Adenocarcinoma. *Medicine (Baltimore)* 2015;94:e1012.
23. Hwang IK, Kim H, Lee YS, et al. The presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. *Cancer Sci* 2015.
24. Kim J. Endoscopic Ultrasound-Guided Treatment of Pancreatic Cystic and Solid Masses. *Clin Endosc* 2015;48:308-11.
25. Kim GH, Chung JW, Lee JH, et al. Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study. *Clin Mol Hepatol* 2015;21:379-86.
26. Lee YS, Kim H, Kim HW, et al. High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor. *Medicine (Baltimore)* 2015;94:e2224.
27. Park JK, Song BJ, Ryu JK, et al. Clinical Outcomes of Endoscopic Ultrasonography-Guided Pancreatic Cyst Ablation. *Pancreas* 2016;45:889-94.
28. Lee JC, Ahn S, Paik KH, et al. Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol. *BMJ Open* 2016;6:e010491.
29. Lee BS, Ryu JK, Jang DK, et al. Reintervention for occluded metal stent in malignant bile duct obstruction: A prospective randomized trial comparing covered and uncovered metal stent. *J Gastroenterol Hepatol* 2016;31:1901-1907.
30. Paik KH, Lee JC, Kim HW, et al. Risk Factors for Gallstone Formation in Resected Gastric Cancer Patients. *Medicine (Baltimore)* 2016;95:e3157.
31. Kim J, Ryu JK, Lee SH, et al. MicroRNA 141 Expression Is a Potential Prognostic Marker of Biliary Tract Cancers. *Gut Liver* 2016;10:836-41.
32. Si WK, Chung JW, Cho J, et al. Predictors of Increased Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. *PLoS One* 2016;11:e0158066.
33. Kang J, Paik KH, Lee JC, et al. The Efficacy of Clinical Predictors for Patients with Intermediate Risk of Cholelithiasis. *Digestion* 2016;94:100-105.
34. Chung JW, Kim BH, Lee CS, et al. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. *PLoS One* 2016;11:e0168189.
35. Choi JH, Kim HW, Lee JC, et al. Percutaneous transhepatic versus EUS-guided gallbladder drainage for malignant cystic duct obstruction. *Gastrointest Endosc* 2017;85:357-364.
36. Kim HW, Lee JC, Paik KH, et al. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. *Medicine (Baltimore)* 2017;96:e5926.
37. Kim HW, Lee JC, Paik KH, et al. Adjunctive role of preoperative liver magnetic resonance imaging for

potentially resectable pancreatic cancer. *Surgery* 2017;161:1579-1587.

38. Kim HW, Lee JC, Lee J, et al. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. *PLoS One* 2017;12:e0173960.
39. Lee JC, Kim JW, Ahn S, et al. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. *Eur J Cancer* 2017;76:125-133.
40. Kim J. Training in Endoscopy: Endoscopic Retrograde Cholangiopancreatography. *Clin Endosc* 2017;50:334-339.
41. Park H, Lee Y, Lee H, et al. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. *Tumour Biol* 2017;39:1010428317718403.
42. Lee Y, Lee H, Park H, et al. Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas. *Oncotarget* 2017;8:76699-76711.
43. Chung JW, Jang ES, Kim J, et al. Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. *Oncotarget* 2017;8:106499-106510.
44. Ahn DW, Lee SH, Paik WH, et al. Effects of Saline Irrigation of the Bile Duct to Reduce the Rate of Residual Common Bile Duct Stones: A Multicenter, Prospective, Randomized Study. *Am J Gastroenterol* 2018;113:548-555.
45. Lee JC, Ahn S, Cho IK, et al. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. *BMJ Open* 2018;8:e017249.
46. Lee JC, Kim H, Kim HW, et al. It is necessary to exam bottom and top slide smears of EUS-FNA for pancreatic cancer. *Hepatobiliary Pancreat Dis Int* 2018;17:553-558.
47. Lee JC, Kim JS, Kim HW, et al. Outcome of endoscopic retrograde cholangiopancreatography in patients with clinically defined decompensated liver cirrhosis. *J Dig Dis* 2018;19:605-613.
48. Lee CH, Yoon H, Choi YJ, et al. Predictive factors of therapeutic intervention in on-call endoscopy for suspected gastrointestinal bleeding. *Scand J Gastroenterol* 2018;53:958-963.
49. Jo JH, Cho CM, Jun JH, et al. Same-session endoscopic ultrasound-guided fine needle aspiration and endoscopic retrograde cholangiopancreatography-based tissue sampling in suspected malignant biliary obstruction: A multicenter experience. *J Gastroenterol Hepatol* 2018.
50. Kim J, Kim H, Lee JC, et al. Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. *PLoS One* 2018;13:e0209104.
51. Lee J, Lee JC, Gromski MA, et al. Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. *Medicine (Baltimore)* 2018;97:e13592.
52. Shin DW, Lee JC, Kim J, et al. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma. *Eur J Surg Oncol* 2019;45:2159-2165.
53. Cho E, Park CH, Kim TH, et al. A prospective, randomized, multicenter clinical trial comparing 25-gauge and 20-gauge biopsy needles for endoscopic ultrasound-guided sampling of solid pancreatic lesions. *Surg Endosc* 2020;34:1310-1317.
54. Cho IK, Kim H, Lee JC, et al. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. LID - 10.5009/gnl19180 [doi]. *Gut Liver* 2019.
55. Park JM, Kang CD, Lee JC, et al. Recent 5-Year Trend of Endoscopic Retrograde Cholangiography in Korea Using National Health Insurance Review and Assessment Service Open Data. LID - 10.5009/gnl19249 [doi]. *Gut Liver*.
56. Kim J, Braun D, Ukaegbu C, et al. Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome. *Clin Gastroenterol Hepatol* 2019.
57. Lee YS, Lee JC, Yang SY, et al. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: A systematic review and meta-analysis. *Sci Rep* 2019;9:15662.
58. Lee JC, Shin DW, Park H, et al. Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: Phase I Trial. *Gastrointest Endosc* 2020.
59. Shin DW, Kim MJ, Lee JC, et al. Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma: A Large Multicenter Study. *Am J Clin Oncol* 2020.
60. Shin DW, Kim J. The American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma: is it better than the 7th edition? *Hepatobiliary Surg Nutr* 2020;9:98-100.